Ectromelia virus, an orthopoxvirus that can cause extensive morbidity and mortality (mousepox) in colonized mice, has been epizootically responsible for serious disruption of biomedical research since 1930. The lack of a sensitive and specific serological assay for infection with this virus became apparent during outbreaks of mousepox at the National Institutes of Health, Bethesda, Md., and other biomedical research institutions in 1979 and 1980. To fill this need, we evaluated an enzyme-linked immunosorbent assay. Sucrose gradient-purified ectromelia and vaccinia viruses were compared as antigens in tests on approximately 1,000 mouse sera from experimentally infected mice and conventional colonies of uninfected mice. A statistical analysis based on the frequency distribution of the absorbance values for 152 mouse sera (free of ectromelia antibody) gave 0.22 as a value to differentiate ectromelia-positive sera from ectromelia-negative sera. When enzyme-linked immunosorbent assay results were compared with those obtained by an indirect immunofluorescence assay, the former was found to be at least 10-fold more sensitive. With the procedures employed, including the use of purified vaccinia virions as antigen, the enzymelinked immunosorbent assay proved to be highly sensitive and specific for detecting antibodies to ectromelia and vaccinia viruses. False-positive results were not encountered. False-negative results were observed in 3% of 108 separate tests of a known positive serum. Although data indicated that ectromelia antibody can be differentiated from vaccinia antibody with homologous and heterologous antigen, this procedure probably cannot be generally used because of unavailability of ectromelia antigens.
Ectromelia virus is an orthopoxvirus which can cause severe disease (mousepox) in laboratory mice (10) . Until 1980, a hemagglutination inhibition (HI) test was the principal assay used to detect antibody to ectromelia virus (2, 5) . However, during the mousepox outbreak at the National Institutes of Health, Bethesda, Md., and several other biomedical research institutions in the United States during 1979 and 1980, it became apparent that the HI test was both insensitive and nonspecific (1, 5, 9, 14) . Since a sensitive and specific serological assay is essential to the control and prevention of mousepox, an enzyme-linked immunosorbent assay (ELISA) was devised and evaluated for this purpose. Herein, we report results from the ELISA on approximately 1,000 sera from a variety of mouse colonies and experimentally infected mice. Both ectromelia and vaccinia viruses were evaluated as antigens. These results were compared with results from tests on some of the same sera with an indirect immunofluorescence assay.
MATERIALS AND METHODS
Cell culture. BS-C-1 (a continuous African green monkey kidney cell line) cells were used exclusively for cultivation of virus. They were grown to confluency in 150-cm2 flasks with Eagle minimal essential medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 U of penicillin and 100 ,ug of streptomycin per ml (Eagle minimal essential medium-10% fetal bovine serum). New cultures were established by conventional methods.
Virus. Ectromelia virus strain NIH 79, which was used for the preparation of virus antigen, was isolated during the outbreak of mousepox at the National Institutes of Health in 1979 and 1980 (1) . The Experimental mouse infections. Six groups of five C57BL/6J mice under methoxyflurane anesthesia were infected with 5 to 10 PFU (in 0.05 ml) of strain NIH 79 by the footpad route of inoculation. Five days later, the first group of five mice was bled as described below. The remaining groups (2 through 6) of mice were bled at 1-day intervals. The bleeding cycle was then repeated. Experimentally infected mice under methoxyflurane anesthesia were bled from the orbital sinus into a sterile, heparin-treated Pasteur pipette. The plasma fraction was collected after centrifugation at 8,740 x g for 5 min and stored at -70°C. (In certain instances, heparin treatment of the Pasteur pipette was omitted from the protocol with no significant effect on the behavior of the serum in the subsequent assays.)
Mouse vaccination. Eight groups of six female BALB/c mice each were vaccinated with vaccinia virus strain IHD-T at the base of the tail by placing a microdrop of virus at the site and stroking a bent 27-gauge needle through the site. Six mice were bled at 0, 3, 7, 11, 15, 21, 28, and 35 days postvaccination. Sera were processed as described below.
Field specimens. Mouse sera and plasma, some of which had been heat inactivated at 56°C for 30 min, were received frozen from various sources.
Control antiserum. Positive reference strain NIH 79 antisera were prepared by pooling sera from experimentally infected BALB/c mice which showed typical ectromelia pathology. Negative control sera were prepared also from other BALB/c mice which had no known exposure to ectromelia virus. These control sera were used in all indirect fluorescent-antibody (IFA) tests and ELISAs. IFA assay. As described above, BS-C-1 cells were infected with strain WR, strain NIH 79, or no virus and harvested when there was extensive cytopathogenic effect. A cell suspension prepared in PBS was centrifuged at 400 x g for 10 min. The supernatant was discarded, and 1.5 ml of PBS was added to 0.5 ml of the cell pellet and thoroughly mixed. From this suspension a volume of 0.02 ml was added to each well (7 mm in diameter) of a "printed" slide, which was air dried at room temperature and then fixed in cold acetone (-20°C) for 20 min. After further air drying at room temperature, the slides were stored at -20°C for a maximum period of 8 weeks.
To detect virus-specific antibodies, wells containing either virus or control antigen were reacted with 0.02 ml of diluted plasma for 20 min at room temperature. Unreacted plasma was removed by three 5-min washes in PBS. The immobilized antigen-antibody complexes were further reacted for 20 min at room temperature with 0.02 ml of affinity-purified fluoresceinconjugated goat anti-mouse immunoglobulin G (IgG) at 150 ,ug/ml (fluorescein/protein ratio of 7) which was kindly supplied by R. Asofsky, National Institutes of Health, Bethesda, Md. Each slide received three further 5-min washes in PBS and was dry blotted with tissue paper. Slides were then overlaid with glycerin barbital buffer, pH 8.6, and examined by using a Leitz microscope with fluorescence epi-illumination (100-W ultra-high-pressure mercury lamp; PLOEMOPAK filter block K2) and a x10-magnification objective lens. Serum was considered positive for virus-specific antibody if there was 2+ or greater fluorescence on a scale of 1 to 4 when compared with known negative and positive control sera included in each test.
ELISA. The procedure for ELISA was modified slightly from that of Murphy et al. (11) . The optimal concentrations of individual reagents were determined by checkerboard titrations (13) , and the assay was carried out as follows. Virus antigen (100 p.l; 1 Second, control antigen (uninfected BS-C-1 cells) prepared in a similar fashion also yielded unacceptably high background levels with both ectromelia antibody-negative and -positive sera at dilutions of less than 1:100 (unpublished data). For these reasons, a purified virus antigen was prepared (7) and used as the solid-phase antigen in the ELISA.
To evaluate the specificity of the binding of the antibody to the immobilized antigen, sera from mouse colonies with no history of mousepox were tested against both virus and a control antigen such as BSA. Because the "conventional" colonies tested consisted of mice housed in nonbarrier facilities and thus were the most representative population of colonies at risk to ectromelia infection, data from these animals were used to construct the criteria for scoring a serum positive or negative with respect to ectromelia antibodies.
Average OD values from tests on two groups of sera, each screened at 1:20, are shown in Table 1 . The first group of 123 was assayed on 3 separate days early in the investigation, and the second group of 29 was assayed on 4 days quite recently. Each collection of sera was subject to variability from two sources: serum-to-serum differences within assays and assay-to-assay differences. The average OD of the group of sera assayed recently is smaller than that of the group done earlier, and the same is true of the respective SDs. These findings are consistent with an increase in assay precision as additional experience with the assay was acquired. A distributional analysis of the data summarized in Table 1 showed that less than 2% of the sera yielded an OD value of equal to or greater than 0.22. In a further test of the specificity of this criterion, sera from a population of 51 mice previously exposed to mouse hepatitis virus were tested by ELISA. The group showed a mean (+SD) OD value of 0.006 +0.024 at a 1:20 serum dilution, and all sera were scored negative by our criterion (unpublished data).
To verify that a negative test score did not simply reflect defective reagents and that a positive result was not due to nonspecific binding of reagents not detected by the BSA control, an immune and a preimmune control serum were analyzed in each test. In each valid test, the preimmune negative serum gave a corrected OD of less than 0.22, whereas an immune serum had a geometric mean ('-SE) titer of 1:34,260 x 1.75 (data from assays on different days) and, in repeat assays, gave absorbance values which were linear and parallel over a range of six twofold serum dilutions. At low serum dilutions, the ELISA reader showed a nonlinear response at an OD of approximately 1.5 and greater. (Fig. 1) . The ELISA detected a rise in ectromelia antibody at day 10 p.i., whereas the IFA titer did not begin to rise until day 13 (on a black background), which had been scored as positive for ectromelia antibody by a number of diagnostic tests, were all confirmed as positive for ectromelia antibody by this ELISA (unpublished data).
Use of homologous and heterologous antigen to distinguish between ectromelia and vaccinia antibodies. Because the ELISA herein described cannot differentiate between vaccinia and ectromelia antibodies, surveillance for ectromelia virus in mouse colonies immunized with vaccinia virus was difficult. Thus, we tested a number of sera from mice experimentally infected with either ectromelia or vaccinia virus, comparing ELISA reactions with the respective purified virion antigens (Tables 2 and 3 ). As might be expected, the ectromelia antibody titer was highest when ectromelia antigen was used in the ELISA; specifically, the mean (± SE) of the 11 ectromelia antigen-vaccinia antigen titer ratios (E/V ratios) from Table 2 was shown to be 3.8 + 0.5. This was significantly (P < 0.01) greater than the corresponding ratio for vaccinia antibody (1.1 ± 0.2), which produced titers to almost equivalent endpoints irrespective of which antigen was employed in the ELISA (Student's t-test). ic serological assay that is easy to perform. Historically, the HI test has been used for this purpose (2) . As a serological assay, its advantages include simplicity, a low unit assay cost, and suitability for a large-scale screening program. In addition, this test does not detect vaccinia antibody in mice that have been immunized with the IHD-T strain of vaccinia virus (2) . However, the HI test is known to be relatively insensitive as compared with the IFA test and the ELISA (4, 5) . During a recent outbreak of ectromelia at the National Institutes of Health and several other large biomedical institutions, it became obvious that the HI test on occasion would yield both false-positive and false-negative results (1, 5, 9, 14) . An (14) . In that case, of 13 We have shown the ELISA to be at least 10-fold more sensitive than the IFA test. The significant deviation from 1.0 of the slope of the regression line (Fig. 2 ) may have been due to the use of purified virus antigen in the ELISA, whereas infected BS-C-1 cells were used in the IFA. The ELISA was shown to be capable of detecting ectromelia antibody by 10 days p.i. It is possible that even earlier detection times could be achieved by using goat anti-mouse IgM conjugate instead of an IgG conjugate. This reagent would be especially valuable during investigations of ongoing outbreaks of ectromelia infection.
Vaccinia virus antigen in an ELISA can specifically detect ectromelia antibody in nonvaccinated mice. However, in mice immunized with vaccinia virus, no method is as yet available to differentiate between ectromelia and vaccinia antibodies. Although it appears ( Tables 2 and 3) that one can differentiate to some extent between vaccinia and ectromelia antibodies on the basis of endpoint titers on homologous and heterologous antigen, the observed overlap of the ratios of ectromelia to vaccinia antibody and the nonavailability of ectromelia antigen limit the utility of this procedure in surveillance programs. In a further attempt to solve this problem, we have isolated a non-cross-reacting specific monoclonal antibody to an abundant epitope on the surface of the vaccinia virus virion. This monoclonal antibody will be used to construct a competitive inhibition ELISA in which vaccinia virus antigen will be used. Mice that are positive for orthopoxvirus antibody in our standard ELISA but are suspected of having been vaccinated with vaccinia virus will be tested by this competitive inhibition assay.
